Analyst Research

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Wuxi Pharmatech (Cayman) Inc raises FY 2014 outlook; gives Q3 2014 outlook in line with analysts' estimates


Wednesday, 13 Aug 2014 04:30pm EDT 

Wuxi Pharmatech (Cayman) Inc:Raised FY 2014 revenue guidance range from the previous $660-$670 mln to $665-$670 million.Increased FY 2014 GAAP diluted earnings per ADS of $1.55-$1.59, compared to previous guidance of $1.53-$1.58.Increased FY 2014 Non-GAAP diluted earnings per ADS of $1.82-$1.86, compared to previous guidance of $1.80-$1.85.Expects Q3 2014 total net revenues of $171-$173 mln.Expects Q3 2014 GAAP diluted earnings per ADS of $0.40-$0.42.Expects Q3 2014 non-GAAP diluted earnings per ADS of $0.48-$0.50.FY 2014 revenue of $669 mln, EPS of $1.84 - Thomson Reuters I/B/E/S.Q3 2014 revenue of $173 mln, EPS of $0.49 - Thomson Reuters I/B/E/S. 

Company Quote

42.33
0.01 +0.02%
4 Sep 2015